Clinical trials
Alzheimer clinical trials
Below are recruiting alzheimer clinical trials, each written for real people, not researchers. We’re tracking 620 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04436081RecruitingPhase 2
CBD oil without THC for agitation in Alzheimer’s dementia
This trial studies whether a THC-free CBD oil softgel can reduce agitation in people with Alzheimer’s-related dementia. It compares CBD to a control to see if it improves difficult behaviors and is safe over the study period.
Norfolk, VirginiaAges 50–90 - NCT04570085RecruitingPhase 3
Caffeine treatment to improve thinking in Alzheimer’s disease
This trial tests whether changing caffeine intake can improve thinking and brain function in people with Alzheimer’s disease. You may qualify if you can follow a low-caffeine diet and have stable Alzheimer’s treatment and sleep/heart conditions.
AmiensAges 50 years+ - NCT04575337Recruiting
Biomarker study to help detect Alzheimer’s early
This study looks for brain/biological “signals” (biomarkers) that may identify Alzheimer’s disease earlier, including stages before clear symptoms. You may be followed for about 5 years, with repeated memory and thinking testing to see how these signs relate to future diagnosis.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04661280RecruitingPhase 3
Donepezil compared with non-drug care for Alzheimer’s
This trial compares donepezil (a medicine for Alzheimer’s symptoms) against a non-drug treatment plan. It aims to see which approach helps people with Alzheimer’s who still have measurable thinking ability and specific Alzheimer’s test results.
ParisAges 50 years+ - NCT04740580RecruitingEarly Phase 1
Test glutathione for brain inflammation in Alzheimer’s
This early-stage study tests whether taking glutathione can affect brain “inflammation” and metabolism in people with Alzheimer’s disease. You might benefit from a new treatment approach, while helping researchers understand what works best for early Alzheimer’s-related brain changes.
Houston, TexasAges 55–85 - NCT04800588Recruiting
Computer tests to study early Alzheimer’s changes
This study uses computer and touch-screen tasks to measure thinking changes in people who may be in the early, symptom-free stage of Alzheimer’s disease. It aims to understand how these brain-related changes show up on testing, which could help future detection or tracking.
Berkeley, CaliforniaAges 18–89 - NCT04804241RecruitingPhase 2
Senicapoc for early Alzheimer’s symptoms
This Phase 2 study tests whether the drug senicapoc can slow or improve symptoms in people with early Alzheimer’s disease or mild memory impairment. You would have a 50/50 chance of getting senicapoc or a placebo (inactive pill), along with regular study visits and testing.
Sacramento, CaliforniaAges 55–85 - NCT04804618Recruiting
Study uses blood protein changes in memory loss and Alzheimer’s
This trial studies blood “protein fingerprints” in people with mild memory problems or Alzheimer’s disease to better understand what’s happening. It may help researchers find ways to measure the condition and improve care over time.
Guangzhou, GuangdongAges 55 years+ - NCT04850053Recruiting
Using brain-related “seeds” to help diagnose Alzheimer’s disease
This study looks for specific markers (“seeds”) that may help doctors diagnose Alzheimer’s disease and distinguish it from other memory or thinking conditions. If you are in the right age range and can complete memory testing and provide a sample, you may help validate a diagnostic approach.
Beijing, Beijing MunicipalityAges 55–75 - NCT04855630Recruiting
Sleep and mild exercise program for thinking and memory support
This study tests whether combining better sleep routines with mild exercise can help with memory, concentration, and thinking speed. To do that, you would wear special devices and complete quick at-home and in-person assessments and a small finger-prick blood test.
Miami, FloridaAges 45–80 - NCT04902703RecruitingPhase 2
GM-CSF drug trial for mild to moderate Alzheimer’s disease
This Phase 2 study tests whether sargramostim (a GM-CSF related medicine) is safe and can slow or improve Alzheimer’s symptoms. You might be a good fit if you have mild or moderate Alzheimer’s, positive amyloid testing, and can complete frequent visits with a close caregiver who knows you well.
Aurora, ColoradoAges 60–85 - NCT04629547RecruitingPhase 2
Sleep study to help prevent Alzheimer’s disease
This trial tests whether treating sleep issues and measuring sleep can help lower the risk of Alzheimer’s disease before it starts. It focuses on older adults with no dementia signs yet.
St Louis, MissouriAges 65 years+ - NCT06274528RecruitingPhase 2
DORA and lemborexant in Alzheimer's biomarkers study
This study is testing whether a sleep medication called lemborexant can improve sleep and reduce Alzheimer's-related proteins in healthy older adults with no memory problems. It could help find new ways to delay or prevent Alzheimer's disease.
St Louis, MissouriAges 65 years+ - NCT05020106Recruiting
Tests Alzheimer’s core blood/brain markers to set diagnostic cutoffs
This study checks Alzheimer’s “core biomarkers” to find the best cut-off values for diagnosing Alzheimer’s disease and related conditions. It may help doctors more accurately tell Alzheimer’s, mild cognitive changes, and other causes of memory problems apart.
Beijing, Beijing MunicipalityAges 55–75 - NCT05020626Recruiting
Uses brain MRI data to study Alzheimer’s disease diagnosis
This study uses brain MRI images to better understand how a protein called tau spreads in Alzheimer’s disease and related conditions. If you’re 55 or older and had an MRI close to your diagnosis, you may be eligible.
Hong Kong, ShatinAges 55 years+ - NCT05059158Recruiting
Study how the brain clears amyloid in Alzheimer’s
This trial studies how the brain removes amyloid-β, a protein linked to Alzheimer’s disease. It may help researchers understand what’s happening in people with mild memory impairment or Alzheimer’s, and guide better treatments in the future.
München, BavariaAges 50–85 - NCT05077579Recruiting
Alzheimer’s scan study for people with higher body weight
This study uses brain scans (MRI and two special PET scans) to see how Alzheimer’s-related changes show up in people who are overweight or obese, with different blood-sugar and insulin patterns. It may help researchers understand whether body weight and metabolism affect early Alzheimer’s markers in the brain.
St Louis, MissouriAges 40–60 - NCT05077618Recruiting
Teeth bacteria study in seniors with and without Alzheimer’s
This study looks at the bacteria in the mouth (periodontal microbiota) to see whether they differ between seniors with Alzheimer’s disease and seniors without it. You may be asked for a sample from your gums/teeth and background health information.
Nice, CHU de NICEAges 18–90 - NCT05151562Recruiting
Music therapy for people with early Alzheimer’s or memory loss
This trial studies whether music therapy can improve symptoms and well-being in people with early Alzheimer’s disease or mild memory problems. You may take part in music sessions and likely be screened with MRI, so the study checks safety for scans.
Baltimore, MarylandAges 18–89 - NCT05187819Recruiting
Blood test to help diagnose possible Alzheimer’s
This trial checks whether a simple blood test can help doctors diagnose Alzheimer’s in people who seem to have memory problems. If you’re being evaluated for possible dementia, your doctor may refer you to a memory clinic for testing and follow-up.
StavangerAges 40–100 - NCT05194787Recruiting
Online tests to spot early Alzheimer’s changes
This study looks at whether online motor (movement) and thinking tasks can detect early changes related to Alzheimer’s disease. You may be able to take part if you’re over 50 and do not already have a diagnosis of dementia.
Hobart, TasmaniaAges 50 years+ - NCT05205980Recruiting
Training practice to help prevent falls in Alzheimer’s
This trial tests whether a specific “training practice” can reduce falls in people with probable Alzheimer’s disease. It may help by improving safe walking and balance after doing the training.
Valdosta, GeorgiaAges 65–90 - NCT05231798RecruitingPhase 2
PET and brain scans in adults with Down syndrome
This study looks at how well a brain chemical system works in adults with Down syndrome as they age, including how it relates to Alzheimer’s-type brain changes and thinking skills. It uses brain scans and memory/thinking tests to see whether these measures can help track risk or changes over time.
Nashville, TennesseeAges 18–55 - NCT05245903Recruiting
Test a supplement and track brain changes with wearable sensors
This study tests whether taking nicotinamide riboside (a form of niacin) affects early memory changes in people with mild cognitive impairment (MCI) or mild Alzheimer’s disease (AD). It also uses passive wearable or sensor data (“digital biomarkers”) to measure changes over time.
Belmont, MassachusettsAges 18–89
Hear when a new Alzheimer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer?
- Yes. Clin2 currently lists 620 recruiting alzheimer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.